PORT WASHINGTON, N.Y.–Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification, today announced its acquisition of MicroReactor Technologies, Inc. (MRT), a privately held U.S. biotechnology company. MRT has developed a reliable, easy-to-use and cost-effective miniature bioreactor technology platform.

“Customers seek better tools for rapid process development and process monitoring. The addition of MRT further broadens Pall Life Sciences support of customers in this rapidly growing market. We welcome the newest members of the Pall family.”

The acquisition of MRT, with its patented approach to high throughput miniature bioreactor equipment and disposables, expands Pall’s Total Fluid ManagementSM (TFM) capabilities in the $1 billion biopharmaceuticals process monitoring and process development market.Terms of the deal were not disclosed.

Speed to market continues to be a critical driver in the biopharmaceuticals industry. High Throughput Process Development (HTPD) is a rapidly emerging approach that enables biotech drug development activities to be accomplished much faster and with less material. Cell culture optimization, as a starting point for new biotech drug development, can greatly benefit from this approach.

Founded in 2003 in Mountain View, California, MRT quickly gained market recognition for its miniature bioreactor platform that is able to improve cell culture process development through fast and accurate assessment of bioreactor performance. Since its first product arrived on the market in 2006, MRT has developed HTPD systems that control, monitor and record key process parameters for multiple individual cell culture experiments in one test sequence.

These systems are proven to simulate the performance of stirred tank bioreactors in both cell culture and microbial fermentation from bench scale (1 to 20L) to much larger scale (up to 200,000L). The disposable bioreactor cassette has 24 individual bioreactors, each of which can be independently controlled and monitored for key parameters, including pH, dissolved oxygen, and temperature.

“We are excited by this acquisition and the increased opportunities it presents for our biotechnology process development and laboratory programs,” said Eric Krasnoff, Pall Corporation Chairman and CEO. “Customers seek better tools for rapid process development and process monitoring. The addition of MRT further broadens Pall Life Sciences support of customers in this rapidly growing market. We welcome the newest members of the Pall family.”

“It is exciting to join Pall and support the rapid growth in our business. More importantly, it enables our customers to exploit on a wider scale, the very significant advantages that the Micro-24 bioreactor technology is bringing to the industry,” said Stephen Boyer, President of MRT.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing Total Fluid ManagementSM solutions to meet the critical needs of customers in biopharmaceutical, hospital and transfusion medicine, energy and alternative energy, electronics, municipal and industrial water, aerospace, transportation and broad industrial markets. Together with our customers, we foster health, safety and environmentally responsible technologies. The company’s engineered solutions enable process and product innovation and minimize emissions and waste. Pall Corporation, with total revenues of $2.3 billion for fiscal 2009, is an S&P 500 company with more than 10,000 employees servicing customers worldwide. Pall has been named a top “green company” by Newsweek magazine. To see how Pall is helping enable a greener and more sustainable future, visit Pall at https://www.pall.com.

Forward-Looking Statements

The matters discussed in this release contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995.

All statements regarding future performance, earnings projections, earnings guidance, management’s expectations about its future cash needs and effective tax rate, and other future events or developments are forward-looking statements. Forward-looking statements are those that use terms such as “anticipate”, “should”, “believe”, “estimate”, “expect”, “intend”, “plan”, “predict”, “potential” or similar expressions about matters that are not historical facts. Forward-looking statements contained in this and other written and oral reports are based on current Company expectations and are subject to risks and uncertainties, which could cause actual results to differ materially. Such risks and uncertainties include, but are not limited to, those discussed in Part I, Item 1A, “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2009, and other reports the Company files with the Securities and Exchange Commission; the impact of the current global recessionary environment and its likely depth and duration; the current credit market constraints, volatility in currency exchange rates and energy costs and other macro economic challenges currently affecting the Company, our customers (including their cash flow and payment practices) and vendors; the effectiveness of our initiatives to mitigate the impact of the current economic environment; and the Company’s ability to successfully complete its business improvement initiatives that include integrating and upgrading its information systems and the effect of a serious disruption in the Company’s information systems on its business and results of operations. The Company makes these statements as of the date of this disclosure and undertakes no obligation to update them.